Miłosz Strugała

Mr. Miłosz Strugała

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
KBKarolina Blady
Karolina Blady
BPBartosz Pomianowski
Bartosz Pomianowski
MSMiłosz Strugała
Miłosz Strugała
LSLeon Smółka
Leon Smółka
KKKarolina Kursa
Karolina Kursa
Agata StanekAgata Stanek
Agata Stanek
Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with immune dysregulation, skin barrier dysfunction, and microbial dysbiosis characterized by Staphylococcus aureus overcolonization and reduced bacterial diversity. Beyond its classical role in calcium homeostasis, Vitamin D (VD) influences skin immunity and microbial composition. This review summarizes current knowledge on VD metabolism, its immunological pathways in AD, and its interactions with the skin microbiome. Recent evidence positions the skin as an active immunological organ rather than a passive barrier. Commensal bacteria such as Staphylococcus epidermidis not only inhibit pathogens by producing bacteriocins and modulins but also generate ceramides and short-chain fatty acids (SCFAs) that stabilize the lipid barrier. Moreover, dermal fibroblasts and preadipocytes produce antimicrobial peptides, while resident γδ T cells release growth factors like fibroblast growth factor 7 (FGF7), linking host defense with tissue regeneration. VD modulates AD by suppressing T helper 2 cells/T helper 17 cell responses, enhancing regulatory T cell development, inducing antimicrobial peptides, and strengthening skin and gut barrier integrity. Its interaction with the microbiome and pathways such as SCFA and aryl hydrocarbon receptor (AhR) signaling supports its potential as an adjunctive therapy in AD management. Evidence from mechanistic studies and animal models suggests that VD supplementation may modulate inflammation and microbial diversity. Clinical implications, therapeutic perspectives, and future research directions highlight the potential of VD as a therapeutic adjunct in AD management.

9 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
LSLeon Smółka
Leon Smółka
MSMiłosz Strugała
Miłosz Strugała
KBKarolina Blady
Karolina Blady
BPBartosz Pomianowski
Bartosz Pomianowski
KKKarolina Kursa
Karolina Kursa
Agata StanekAgata Stanek
Agata Stanek
Aortic diseases, including abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), aortic dissection (AD), and Takayasu arteritis (TAK), are characterized by vascular remodeling and chronic immune–inflammatory activation, with AD often representing an acute complication of long-standing aortic wall vulnerability. Increasing evidence suggests that gut dysbiosis, impaired intestinal barrier integrity, and microbiota-derived metabolites may contribute to aortic wall injury. We synthesized current evidence linking the gut microbiome to aortic diseases and explored potential translational implications. PubMed, Scopus, and Web of Science were searched for microbiome-related studies on AAA, TAA, AD, and TAK published up to December 2025. Human observational and interventional studies were integrated with relevant experimental research. The strongest evidence was identified for AAA, where multiple cohorts report gut dysbiosis and reduced microbial diversity. Translational studies have detected bacterial DNA and microbial products in blood, aneurysm wall, or intraluminal thrombus, consistent with barrier-related microbial signaling and vascular inflammation, although these low-biomass findings do not establish microbial viability or causality. Microbiota-derived mediators—including trimethylamine-N-oxide, lipopolysaccharides, short-chain fatty acids, and bile acid derivatives—interact with pathways involved in cytokine signaling, oxidative stress, innate immune activation, and extracellular matrix degradation. Evidence for TAA and AD remains limited and suggests mainly modifier effects, whereas early studies in TAK indicate disease-associated microbiome and metabolite alterations. Mendelian randomization analyses have explored genetically proxied microbiome–AAA associations; however, results are heterogeneous, and causal inference remains provisional. Overall, the gut microbiome emerges as a plausible modifier of aortic disease, with the greatest translational relevance in AAA, highlighting the need for longitudinal multi-compartment studies and targeted interventions with aortic endpoints.

15 December 2025 in Przeglad Epidemiologiczny
Verified
Journal Article
Open access
LSLeon Smółka
Leon Smółka
MSMiłosz Strugała
Miłosz Strugała
KKKarolina Kursa
Karolina Kursa
BPBartosz Pomianowski
Bartosz Pomianowski
KBKarolina Blady
Karolina Blady
KBKrzysztof Bratek
Krzysztof Bratek
Atherosclerosis is a chronic, progressive process affecting medium and large arteries, while peripheral artery disease (PAD) represents one of its clinical manifestations in the limb arteries. Although classical risk factors such as poor diet, hypertension, diabetes, and smoking are well established, increasing evidence indicates that the gut microbiome is an important and modifiable contributor to vascular pathophysiology. This paper reviews current knowledge on the role of the gut microbiome in the initiation and progression of atherosclerosis and PAD, with emphasis on bacterial metabolites, proinflammatory mechanisms, and potential therapeutic interventions. Gut dysbiosis—an imbalance in the intestinal microbial community—has been associated with increased cardiovascular risk. Patients with vascular diseases show higher levels of pro-atherogenic taxa, including Enterobacteriaceae, Streptococcus spp., Lachnoclostridium, and Family XI, alongside a reduction of beneficial short-chain fatty acid (SCFA)-producing bacteria such as Roseburia, Faecalibacterium, Coprococcus2, and Ruminococcaceae. Two key microbial metabolites influence vascular health. Trimethylamine N-oxide (TMAO), formed from choline and L-carnitine via microbial and hepatic metabolism, promotes endothelial dysfunction, inflammation, and platelet reactivity, thereby accelerating atherosclerosis. Conversely, SCFAs—acetate, propionate, and butyrate—exert anti-inflammatory effects, improve insulin sensitivity, and enhance nitric oxide synthesis, resulting in vascular protection. Therapeutic strategies targeting the gut microbiota show promising potential. These include the use of probiotics and prebiotics (notably Lactobacillus rhamnosus GG), adherence to a Mediterranean diet, and fecal microbiota transplantation (FMT), all aimed at restoring eubiosis and a favorable intestinal metabolic profile. In summary, the gut microbiome appears to be a key modulator of the pathogenesis of atherosclerosis and PAD. Targeted modulation of gut microbial composition and activity may emerge as an innovative and effective strategy for the prevention and treatment of cardiovascular diseases.

14 April 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
LSLeon Smółka
Leon Smółka
MSMiłosz Strugała
Miłosz Strugała
KBKarolina Blady
Karolina Blady
KKKarolina Kursa
Karolina Kursa
BPBartosz Pomianowski
Bartosz Pomianowski
Agata StanekAgata Stanek
Agata Stanek
Background: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is increasingly recognized as a thromboinflammatory disorder involving coagulation, innate immunity, endothelial dysfunction, and vascular homeostasis. Emerging evidence suggests that gut microbiome-related inflammatory and metabolic signals may influence pathways potentially relevant to VTE through intestinal barrier dysfunction, microbial translocation, and microbiome-derived metabolites. This review critically examines the direct and indirect evidence relating gut dysbiosis to mechanisms potentially relevant to venous thrombogenesis. Methods: A structured literature search of PubMed, Scopus, and Web of Science was conducted from database inception to February 2026. Observational, translational, experimental, preclinical, and selected genetic studies were narratively synthesized across heterogeneous evidence types. Results: Available evidence suggests that intestinal barrier dysfunction and microbial translocation may increase systemic exposure to lipopolysaccharide and other microbial products, potentially contributing to inflammatory signaling and procoagulant responses. Proposed downstream effects include tissue factor (TF) activation, platelet reactivity, neutrophil extracellular traps (NETs) formation, complement signaling, endothelial perturbation, and impaired balance of anticoagulant and fibrinolytic pathways. Microbiome-derived metabolites, including trimethylamine N-oxide (TMAO), phenylacetylglutamine (PAGln), bile acids, and short-chain fatty acids (SCFAs), have been linked, mainly in experimental or non-VTE settings, to thrombosis-related biology. However, most evidence remains indirect, associative, or experimental, whereas direct human VTE-specific evidence is limited and heterogeneous. Conclusions: The gut microbiome–VTE axis is biologically plausible and supported mainly by mechanistic and indirect evidence, but current data are insufficient to support strong causal conclusions. Further longitudinal, well-phenotyped, mechanistically informed studies are needed to determine whether microbiome-related pathways have measurable clinical relevance in human VTE.

25 April 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
KBKarolina Blady
Karolina Blady
BPBartosz Pomianowski
Bartosz Pomianowski
LSLeon Smółka
Leon Smółka
MSMiłosz Strugała
Miłosz Strugała
KKKarolina Kursa
Karolina Kursa
Agata StanekAgata Stanek
Agata Stanek
Atopic dermatitis (AD) is a chronic inflammatory skin disease with a complex pathogenesis involving epidermal barrier dysfunction, microbiome dysbiosis, and immune dysregulation. Despite significant advances in therapy, including biologics and targeted treatments, their use may be limited by adverse effects, highlighting the need for safe adjunctive strategies. Polyphenols are naturally occurring bioactive compounds that are abundant in plant-based foods and are known for their anti-inflammatory, antioxidant, and immunomodulatory properties, making them promising candidates for supportive AD management. This review integrates current evidence on the effects of polyphenols on epidermal barrier lipids, microbiome interactions, and key inflammatory pathways, including NF-κB and JAK/STAT signaling. Additionally, the role of polyphenols in modulating dendritic cell and neutrophil activity, and reducing reactive oxygen species (ROS) production and neutrophil extracellular trap (NET) formation, as well as their potential involvement in mitophagy regulation, is discussed. Polyphenols support epidermal barrier integrity by modulating the expression of key structural proteins, including filaggrin, involucrin, and loricrin, leading to a reduction in transepidermal water loss (TEWL). Furthermore, they interact bidirectionally with the gut microbiome, acting as metabolic substrates for beneficial bacteria and promoting the growth of short-chain fatty acid (SCFA)-producing species such as Lactobacillus, Bifidobacterium, and Akkermansia, while simultaneously inhibiting pathogenic strains. These findings highlight the role of polyphenols in maintaining microbiome homeostasis and supporting epidermal barrier integrity. The review encompasses findings from clinical studies, animal models, and mechanistic investigations, while also addressing limitations related to polyphenol bioavailability. Overall, polyphenols may represent a valuable adjunctive approach in AD management; however, further well-designed clinical and mechanistic studies are required to confirm their therapeutic potential.

27 November 2025 in Indian Journal of Orthopaedics
Verified
Journal Article
Open access
PDF file
BPBartosz Pomianowski
Bartosz Pomianowski
LSLeon Smółka
Leon Smółka
KBKarolina Blady
Karolina Blady
MSMiłosz Strugała
Miłosz Strugała
KKKarolina Kursa
Karolina Kursa
AWAgnieszka Woźniak
Agnieszka Woźniak
Background: Excessive smartphone use has become an integral part of daily life among young adults, potentially leading to repetitive strain conditions involving the tendons of the wrist. One of the most frequent disorders linked to such overuse is de Quervain’s tenosynovitis, which affects the tendons within the first dorsal compartment. As mobile device use continues to rise worldwide, understanding its musculoskeletal implications is essential for prevention and early clinical management. Aim: This study aimed to examine the association between smartphone usage patterns—specifically screen time and unlocking frequency—and clinical signs consistent with de Quervain’s tenosynovitis in young adults, with special attention to the dominant hand. Materials and Methods: Data were obtained from an original cross-sectional survey assessing smartphone usage behaviors, addiction severity (Smartphone Addiction Scale-Short Version, SAS-SV), and musculoskeletal symptoms using the Finkelstein maneuver. A total of 202 participants were included in the analysis. Statistical evaluation employed Spearman’s rank correlation, Mann–Whitney U tests, and logistic regression to identify relationships between device usage, addiction level, and pain occurrence in the dominant hand. Results: The findings demonstrated a significant positive association between the intensity of smartphone use and self-reported wrist pain. Pain correlated moderately with both the number of phone unlocks ( ρ = 0.596, p < 0.001) and daily screen time ( ρ = 0.524, p < 0.001). Participants classified as addicted according to the SAS-SV scale exhibited greater usage intensity, which corresponded with increased pain prevalence. Conclusions: Frequent and prolonged smartphone use, reflected by higher unlocking frequency and screen exposure time, was significantly associated with clinical features suggestive of de Quervain’s tenosynovitis in the dominant hand. Users meeting the criteria for smartphone addiction showed greater symptom severity. The diagnosis was based exclusively on clinical examination without imaging confirmation.